Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Laura Mazzera"'
Autor:
Laura Mazzera, Manuela Abeltino, Guerino Lombardi, Anna Maria Cantoni, Roberto Ria, Micaela Ricca, Ilaria Saltarella, Valeria Naponelli, Federica Maria Angela Rizzi, Roberto Perris, Attilio Corradi, Angelo Vacca, Antonio Bonati, Paolo Lunghi
Publikováno v:
Haematologica, Vol 104, Iss 12 (2019)
Considering that Aurora kinase inhibitors are currently under clinical investigation in hematologic cancers, the identification of molecular events that limit the response to such agents is essential for enhancing clinical outcomes. Here, we discover
Externí odkaz:
https://doaj.org/article/9af9f48142a54c6ea530496b153bde16
Autor:
Paolo Lunghi, Antonio Bonati, Vittorio Rizzoli, Antonio Costanzo, Massimo Levrero, Laura Mazzera
Publikováno v:
Clinical Cancer Research. 15:6495-6502
The p53 tumor suppressor is part of a small family of related proteins that includes two other members, p73 and p63. Interest in the p53 family members, their functions and their complex interactions and regulation, has steadily grown over recent yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e23da2c15e76dcc16e522da56a6e8f82
https://doi.org/10.1158/1078-0432.ccr-09-1229
https://doi.org/10.1158/1078-0432.ccr-09-1229
Autor:
Vittorio Rizzoli, Roberta Riccioni, Antonio Bonati, Antonio Costanzo, Paolo Lunghi, Nicola Giuliani, Guerino Lombardi, Laura Mazzera, Massimo Levrero, Anna Maria Cantoni, Ugo Testa, Luigi Salvatore, Micaela Ricca, Attilio Corradi
We demonstrate that blockade of the MEK/ERK signaling module, using the small-molecule inhibitors PD184352 or PD325901 (PD), strikingly enhances arsenic trioxide (ATO)–induced cytotoxicity in human myeloma cell lines (HMCLs) and in tumor cells from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfcab2f02b5121fc3f8e77f5dbac0e3a
http://hdl.handle.net/11573/13208
http://hdl.handle.net/11573/13208
Autor:
Simona Colla, Marcellina Mangoni, Antonio Bonati, Paolo Lunghi, Lara Ravanetti, Antonino Neri, Sabrina Bonomini, Vittorio Rizzoli, Francesca Morandi, Marco Ladetto, Luca Ferrari, Tauro Maria Neri, Cristina Mancini, Laura Mazzera, Angela Greco, Claudia Miranda, Nicola Giuliani, Gaetano Donofrio, Davide Martorana, Sara Tagliaferri, Mirca Lazzaretti
Angiogenesis has a critical role in the pathophysiology of multiple myeloma (MM); however, the molecular mechanisms underlying this process are not completely elucidated. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfc51b93b3167e611e9749164b53ecfe
http://hdl.handle.net/2434/41834
http://hdl.handle.net/2434/41834
Autor:
Antonio Costanzo, Antonio Bonati, Laura Mazzera, Antonio Tabilio, Luigi Salvatore, Paolo Lunghi, Nélida I. Noguera, Francesco Lo-Coco, Massimo Levrero
Publikováno v:
Blood. 107(11)
We found that MEK1 inhibitor PD184352 strikingly increased apoptosis induced by arsenic trioxide (ATO) in 21 of 25 patients with primary acute myelogenous leukemia (AML). Isobologram analysis confirmed the synergistic (13 of 25 patients) or additive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21570766e3c76968b084bd7fa9fcd366
https://pubmed.ncbi.nlm.nih.gov/16467208
https://pubmed.ncbi.nlm.nih.gov/16467208
Autor:
Davide Arienti, Guerino Lombardi, Laura Mazzera, Anna Maria Cantoni, Paolo Lunghi, Antonio Bonati, Manuela Abeltino, Micaela Ricca, Attilio Corradi
Publikováno v:
Web of Science
Abstract 1846 Although novel drugs such as Bortezomib and Thalidomide have extended the overall survival of multiple myeloma patients they often do not achieve lasting cures, providing an impetus to search for novel therapeutic modalities. Tumor necr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d0ac35bdf8391693f93f45ba6697f13
https://doi.org/10.1182/blood.v118.21.1846.1846
https://doi.org/10.1182/blood.v118.21.1846.1846
Publikováno v:
Blood. 116:4059-4059
Abstract 4059 Despite advances in chemotherapy and stem-cell transplantation, which have improved survival rates, multiple myeloma (MM) remains an incurable disease. Therefore, new treatment approaches are needed to improve the outcome of MM therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d437d1e341facffbf03142a2ac530aba
https://doi.org/10.1182/blood.v116.21.4059.4059
https://doi.org/10.1182/blood.v116.21.4059.4059
Autor:
Antonio Bonati, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Anna Maria Cantoni, Michael W. Deininger, Vittorio Rizzoli, Paolo Lunghi, Attilio Corradi, Davide Arienti, Stefano Jottini
Publikováno v:
Web of Science
Abstract 2177 Poster Board II-154 Resistance toward Imatinib and other Bcr-Abl tyrosine kinase inhibitors remains an increasing clinical problem in the treatment of advanced stages of chronic myeloid leukemia. Thus novel therapeutic strategies are ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::712b0410a2c88b54a91623edd7d8154c
https://doi.org/10.1182/blood.v114.22.2177.2177
https://doi.org/10.1182/blood.v114.22.2177.2177
Autor:
Laura Mazzera, Antonio Bonati, Anna Maria Cantoni, Nicola Giuliani, Antonio Costanzo, Roberta Riccioni, Attilio Corradi, Luigi Salvatore, Ugo Testa, Micaela Ricca, Vittorio Rizzoli, Guerino Lombardi, Massimo Levrero, Paolo Lunghi
Publikováno v:
Web of Science
ResearcherID
ResearcherID
Despite recent advances in therapy, Multiple myeloma (MM) remains incurable because of the high resistance to apoptosis and both intrinsic and acquired drug resistance. Therefore, new therapeutic strategies are needed to improve patient outcome. We r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c0bd972b0ec76252ebf9c9a6feed158
https://doi.org/10.1182/blood.v112.11.1712.1712
https://doi.org/10.1182/blood.v112.11.1712.1712
Autor:
Paolo Lunghi, Antonio Bonati, Laura Mazzera, Vittorio Rizzoli, Nicola Giuliani, Marcellina Mangoni, Francesca Morandi, Luigi Salvatore
Publikováno v:
Blood. 110:1517-1517
Multiple Myeloma (MM) cells are extremely resistant to apoptosis and currently new potential drug combinations are under investigation. We have shown that the combined treatment with the MEK1/2 inhibitor PD184352 (PD) and Arsenic Trioxide (ATO) resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e3b75112312e6eccb7b53feff4d3fd0
https://doi.org/10.1182/blood.v110.11.1517.1517
https://doi.org/10.1182/blood.v110.11.1517.1517